Data on comparative effectiveness among weight-loss medications (WLMs) in real-world studies (RWS) are limited. The aim of the XENSOR study was to assess in a real-world setting the effectiveness of two WLMs, orlistat and liraglutide, in patients with obesity and insufficient weight loss (WL) after a lifestyle modification program.

A retrospective RWS was conducted comparing clinical outcomes of orlistat 120 mg tid and liraglutide (up to 3 mg daily) in adult patients with BMI ≥ 30 kg/m² (or ≥ 27 kg/m² with at least a weight-related comorbidity) who had failed to lose at least 5% of their baseline weight (BW) after 6 months (mo) of lifestyle modification. The co-primary end points, assessed at 3-6 mo (visit 2) and at the end of the follow-up (visit 3), were weight change from baseline, proportion of patients who lost at least 5% of their BW and adjusted differences in WL between both drugs.

Five hundred patients, 400 in the group of orlistat (women 75%, mean age 47.0 y, mean BW 107.8 kg), and 100 in the group of liraglutide (women 73%, mean age 51.9 y, mean BW 105.1 kg), were included. Treatment with both drugs significantly reduced weight, FPG, systolic BP, LDL-C and ALT over a median follow-up period of 7 mo. WL with liraglutide at visit 3 (-7.7 kg) was significantly greater than that observed with orlistat (-3.3 kg), adjusted mean difference -4.7 kg (95% CI -6.4 to -2.9 kg). More individuals lost at least 5% of their BW with liraglutide (64.7%) than with orlistat (27.4%) at visit 3, p<0.0001. In the subset of patients with prediabetes at baseline, persistence of prediabetes or progression to T2DM was significantly lower with liraglutide (34.6%) than with orlistat (82.8%), p<0.0001. At 12 mo of follow-up, 61% of patients remained on liraglutide, compared to 46.8% on orlistat (p 0.011).

In summary, in this RWS, liraglutide showed a greater effectiveness in WL compared to orlistat and improved several obesity-associated metabolic and cardiovascular risk factors.


J.J. Gorgojo-Martinez: Advisory Panel; Self; Abbott, AstraZeneca, Lilly Diabetes, Mundipharma, Novo Nordisk Inc., Pfizer Inc. Research Support; Self; Novo Nordisk Inc. Other Relationship; Self; Abbott, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Lilly Diabetes, Merck Sharp & Dohme Corp., Mundipharma, Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Pfizer Inc. B. Basagoiti-Carreño: None. A. Sanz-Velasco: Other Relationship; Self; Boehringer Ingelheim Pharmaceuticals, Inc. C. Serrano-Moreno: Other Relationship; Self; Novo Nordisk A/S. F. Almodóvar-Ruiz: Other Relationship; Self; Novo Nordisk Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at